Double your impact Match My Donation
Some will say that immunotherapy became a household word in 2015. That’s in large part to the significant number of FDA approvals. Checkpoint blockade—called so because they “release the brakes” on the immune system, allowing it to mount a stronger and more effective attack against cancer—was FDA approved for melanoma, lung cancer, and kidney cancer. A new type of immunotherapy—oncolytic virus therapy—got approval in October to treat melanoma. And there are now more than 20 approved antibody-based drugs, including new immunotherapies for neuroblastoma and multiple myeloma. Let’s take a look!
2015 was a great year for cancer immunotherapy, and we expect it to be the same in 2016 and beyond, with more treatments—therapeutic vaccines, CAR T cell therapy—joining the list. Stay tuned!
CRI Scientific Advisory Council Member Elected NAI Fellow
Read Previous Article
William Coley and Cancer Immunotherapy Spotlighted on NPR
Read Next Article
*Immunotherapy results may vary from patient to patient.
Cancer Research Institute | National Headquarters
29 Broadway, Floor 4 | New York, NY 10006-3111
(800) 992-2623(212) 832-9376Staff Directory
We spoke with six CRI-funded scientists who have worked in Allison’s lab about their experiences and the impact he’s made on their lives and careers before the Nobel Prize ceremony on Monday, December 10, 2018.
The 2018 American Society of Hematology meeting will showcase a variety of basic and clinical advances in blood cancers like leukemia, lymphoma, and myeloma.